Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy : Analysis of the EMPHASIS-HF study

Krum, HenryShi, HarryPitt, BertramMcMurray, JohnSwedberg, Karlvan Veldhuisen, Dirk J.Vincent, JohnPocock, Stuart J.Zannad, Faiez2025-10-1720131941-328910.1161/CIRCHEARTFAILURE.112.000173https://hdl.handle.net/20.500.14802/31681In EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure), eplerenone significantly reduced major cardiovascular events versus placebo in 2737 patients with mild symptoms of heart failure and an ejection fraction of <35%, in addition to recommended therapy. However, it is not known whether such benefits were preserved in patients receiving optimal background drug therapy, that is, high doses of angiotensin-converting enzyme inhibitor (ACEi, or angiotensin receptor blocker), β-blocker, or both drug classes.ACE inhibitoraldosteroneangiotensin receptor blockerβ-blockereplerenoneheart failureClinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy : Analysis of the EMPHASIS-HF studyJournal article2-s2.0-84884644195Open accessControlled201046012